Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.
äŒæ¥ã³ãŒãTTNP
äŒç€ŸåTitan Pharmaceuticals Inc
äžå Žæ¥Jan 18, 1996
æé«çµå¶è²¬ä»»è
ãCEOãMr. Weei Jye Chay
åŸæ¥å¡æ°- -
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Jan 18
æ¬ç€Ÿæåšå°Suite 505
éœåžSAN FRANCISCO
蚌åžååŒæNASDAQ Capital Market Consolidated
åœUnited States of America
éµäŸ¿çªå·94080
é»è©±çªå·14152444990
ãŠã§ããµã€ãhttps://www.titanpharm.com/
äŒæ¥ã³ãŒãTTNP
äžå Žæ¥Jan 18, 1996
æé«çµå¶è²¬ä»»è
ãCEOãMr. Weei Jye Chay
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã